Fumaric Acid

Fumaric Acid

SCHEMBL2266930

Cn1nccc1CCOc1ccc(N2CCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)cc1.O=C(O)/C=C/C(=O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNH2 known ✓ Q12809 6/20 0.69
KMT2A known ✓ Q03164 1/20 0.38
AR P10275 9/20 0.69
MAPT P10636 2/20 0.50
HPGD P15428 1/20 0.50
BRD4 O60885 4/20 0.49
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 1/20 0.42
XBP1 P17861 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL2266933 1.00 AR (0.69) ARKCNH2MAPTHPGDBRD4
SCHEMBL2266148 0.93 AR (0.79) ARKCNH2MAPTHPGDBRD4
SCHEMBL2264885 0.82 AR (0.72) ARKCNH2MAPTHPGDBRD4
SCHEMBL2266449 0.82 AR (1.00) ARKCNH2BRD4ALOX15HTT
SCHEMBL2271254 0.80 AR (0.60) ARKCNH2MAPTHPGDBRD4
SCHEMBL752905 0.78 MAPT (0.65) ARKCNH2MAPTHPGDBRD4
SCHEMBL748521 0.77 MAPT (0.64) ARKCNH2MAPTHPGDBRD4
SCHEMBL2265371 0.76 MAPT (0.65) ARKCNH2MAPTHPGDBRD4
SCHEMBL748875 0.76 AR (0.73) ARKCNH2MAPTHPGDBRD4
Potassium Ion SCHEMBL751004 0.75 MAPT (0.61) ARKCNH2MAPTHPGDBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003649-B2 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 ASTRAZENECA AB (SE) 2011-08-23 US disclosed
EP-2235010-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20100016279-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 ASTRAZENECA AB (SE) 2010-01-21 US disclosed
WO-2009081197-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS ASTRAZENECA AB (SE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016279-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 AR, NR5A1, CYP17A1 KCNH2 4406/4885KMT2A 3283/4885AR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.